Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label single-arm study of CX13-608 in relapsed or refractory multiple myeloma
CTR20202322Phase 2Active
- Sponsor
- Ningbo Shengjian Biomedical Technology
- Start
- Nov 2020
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CX13-608 in multiple myeloma (MM), sponsored by Ningbo Shengjian Biomedical Technology. Started Nov 2020; status: active.
02
Drugs
CX13-608
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20202322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202322.